There is still significant unmet need within select cardiovascular/metabolic (CVM) disorders. Unfortunately, the cost of developing drugs and devices in this area has been rising steadily. TCR, a full service provider, takes a data-driven approach to developing strategies that will cut timelines and costs. From First-in-Human (FIH) studies through post approval. We have experience conducting cardiovascular trials, with particular emphasis on cardiovascular/metabolic indications: heart failure, lipid disorders, diabetes, renal insufficiency and renal transplant, arrhythmia, medical devices and rare diseases.